Takeda Pharmaceuticals Company, Ltd., emerged as the leading market player with its approved drug Amitiza, and is among the top three players in the global opioid induced constipation market. Along with Boehringer Ingelheim and Valeant Pharmaceuticals International, Ltd., the company holds a massive 91.8% share in the global opioid induced constipation treatment market.
In this highly consolidated market, the leading enterprises are majorly domiciled in North America, leaving immense scope for penetration into other regions.
In a recent study, Transparency Market Research (TMR) reveals opportunities that the market players can capitalize on to improve their global standing. This includes strategies to reach out to emerging nations and gain shares in untapped markets. Based on in-depth research, TMR forecasts a highly positive CAGR of 31.2% between 2015 and 2023, for the global opioid induced constipation treatment market. If this holds true the market is expected to generate revenue worth US$731.2 mn by the end of 2016 and reach US$4.81 bn by the end of 2023.
Chloride channel activators are more popular as drug class among currently available opioid induced constipation treatments. However with time, PAMORAs are likely to generate revenue worth US$2.41 bn by the end of 2023. Regionally, North America will continue dominating the global market through the course of the forecast period. By the end of 2023, the valuation of the North America opioid induced constipation treatment market is expected to reach US$4.05 bn.
Imminent Approval of OIC Drugs to Fuel Growth Opportunities
“The leading driver of the global opioid induced constipation treatment market is the awaited approval for various drugs that are still in the pipeline,” said a lead TMR analyst. “For instance, Naldemedine is one of the leading contenders for approval, post which the market players are certain to witness a spike in the demand,” he added.
Furthermore, the market is also expected to gain from the increasing development of peripheral mu-opioid receptors. With this, a higher preference towards OIC-specific treatments is likely. As PAMORAs do not interfere with opioid action on a patient’s pain and ensure effective treatment of OIC, TMR expects their demand to surge exponentially in the near future thus providing impetus to the global opioid induced constipation treatment market.
Standard Laxatives Still Pose Threat to the Market
On the flip side, the widespread consideration of standard laxatives for the treatment of OIC is a major challenge for the market. Disparity between the pricing of standard laxatives and the targeted OIC medications is the primary reason behind this hindrance. Besides this, the market players also need to work on the relatively under-researched position of opioid induced constipation treatments and drugs. As many of these drugs show side-effects, including nausea and increasing the risk of strokes and heart diseases, not many patients or their families are in favor of administering them.
A way out of this is to improve the scope of development for opioid induced constipation treatments market. The aim should be to reduce the side effects of these drugs and improve their efficacy. The market players can also gain from the opportunities existing in giant untapped market and investing increasingly in R&D and marketing efforts.
This review is based on a TMR study, titled “Opioid Induced Constipation Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023.”
The report segments the global opioid induced constipation treatment market as:
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453